Alzheimer's disease drug development: old problems require new priorities. - Test2 - elhamkhani - TriplyDB

Alzheimer's disease drug development: old problems require new priorities.

Alzheimer's disease drug development: old problems require new priorities.

http://www.wikidata.org/entity/Q37363992

about

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception The Alzheimer's disease neuroimaging initiative: progress report and future plans 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Investigational drugs for the treatment of AD: what can we learn from negative trials?Natural products as promising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect.A new regulatory road-map for Alzheimer's disease drug development Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?Lost in translation: neuropsychiatric drug development.Advances in Alzheimer therapy: understanding pharmacological approaches to the disease.Humanin Specifically Interacts with Amyloid-β Oligomers and Counteracts Their in vivo Toxicity.

P2860

Q27006831-BCD9CD75-DAA6-4D97-8A0B-55424389E655 Q28749585-B394B6FF-6F94-4B89-8BFC-B05887271D10 Q30971403-A6624ECF-A0C0-4A9F-9660-2607AE622035 Q34065449-6536AD77-DAF1-4CC8-913A-EC1EA493E7D3 Q35579234-630BEB07-1C75-4CCE-A92E-EABBCEA8CF77 Q37098664-EEFFD8C0-2ACF-4EA7-B175-66EA2118F4F4 Q37510270-F2D172FE-C955-47C9-9031-73035C8EF759 Q37524877-37F6519A-AE60-41A6-8C88-10CA95B45482 Q37527193-066F302B-6B79-46AB-AB17-838887FAEDEE Q37536106-A225BA62-DF87-4D62-86C2-F0B2DAB4664B Q46405748-0DC5E72A-380B-42F9-8CB3-A7E742FF3B05

P2860

Alzheimer's disease drug development: old problems require new priorities.

http://www.wikidata.org/entity/Q37363992

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Alzheimer's disease drug development: old problems require new priorities.

@en

Alzheimer's disease drug development: old problems require new priorities.

@nl

type

label

Alzheimer's disease drug development: old problems require new priorities.

@en

Alzheimer's disease drug development: old problems require new priorities.

@nl

prefLabel

Alzheimer's disease drug development: old problems require new priorities.

@en

Alzheimer's disease drug development: old problems require new priorities.

@nl

P1433

Q37363992-8C348D37-EB86-4734-AA9A-E8203D8D5A3E

P1476

Q37363992-D37857F5-3D6C-4EAD-A3E5-4369F563520A

P2093

Q37363992-573DABA8-4947-40D2-BC59-33F69CB37411

Q37363992-BC0C787B-CAF4-48F6-8E2D-1829E0365FCC

P2860

Q37363992-085E8B9A-155B-4FCC-940A-9B871913397F

Q37363992-0B1051C2-5E35-4025-A6A5-9B0BD2AE36AA

Q37363992-14B88DAC-0C66-4D4C-9A2E-CAA980F94DE5

Q37363992-1B64F7A3-044D-4661-AF1A-C98D2DA158C1

Q37363992-22FE0822-2163-4916-B907-C019CC80358A

Q37363992-25F950E9-2F3D-43FD-869B-2CB348B095D7

Q37363992-29A077CC-DEE3-4072-A9B3-E3137AAE395F

Q37363992-35BB143B-3992-4117-A8F8-594327A15163

Q37363992-3FB1A4E5-0894-46D0-8F7F-2AC5E1463FE7

Q37363992-3FF82047-EC07-4698-BCD7-E9727E9DF576

P304

Q37363992-930C6202-DED9-4EAE-A6F3-A2E44B1089D5

P31

Q37363992-C1F7F90B-AFD8-49FF-816C-56A1C33D6AEB

P356

Q37363992-4B02B390-7C1A-482D-9AA0-279CE1F40D1E

P433

Q37363992-13D1BD01-0C6A-430B-95B9-6EA5A1B90482

P478

Q37363992-E4142A9E-D659-42A5-BA22-1C603211DA00

P577

Q37363992-4E3ED229-8CDB-4F61-8AA6-C765C52280BB

P5875

Q37363992-606E9565-AE52-45F7-A7E6-432609831FD8

P698

Q37363992-E56282E3-378A-4040-9AE1-D4FCAB20304C

P921

Q37363992-A635509F-5EB8-4590-8D2D-7EF2A9554C91

P932

Q37363992-9F1FDB87-20C4-49E4-B7CA-2A3F61A44B92

P356

187152708787122950

P1433

CNS and Neurological Disorders

P1476

Alzheimer's disease drug development: old problems require new priorities.

@en

P2093

Nigel H Greig

http://www.w3.org/2001/XMLSchema#string

Robert E Becker

http://www.w3.org/2001/XMLSchema#string

P2860

Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials

Biomarkers and surrogate endpoints

Debate: The slippery slope of surrogate outcomes

A perfect correlate does not a surrogate make

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

PET imaging of amyloid in Alzheimer's disease.

The role of biomarkers in clinical trials for Alzheimer disease

A structured interview guide for the Hamilton Depression Rating Scale.

Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.

P304

499-511

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/187152708787122950

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23763087

http://www.w3.org/2001/XMLSchema#string

P698

19128207

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

5175454

http://www.w3.org/2001/XMLSchema#string